Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mesothelioma and SCLC

2692 - Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial

Date

10 Sep 2017

Session

Mesothelioma and SCLC

Presenters

Gerard Zalcman

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

G. Zalcman1, J. Mazieres2, L. Greillier3, S. Lantuejoul4, P. Dô5, O. Bylicki6, I. Monnet7, R. Corre8, C. Audigier-Valette9, M. Locatelli-Sanchez10, O. Molinier11, L. Thiberville12, T. Urban13, D. Planchard14, C. Ligeza-Poisson15, E. Amour16, F. Morin16, D. Moro-Sibilot17, A. Scherpereel18

Author affiliations

  • 1 Thoracic Oncology, Hôpital Bichat-Claude Bernard, Université Paris-Diderot, 75018 - Paris/FR
  • 2 Pulmonology And Thoracic Oncology, Hôpital Larrey, CHU Toulouse, Toulouse/FR
  • 3 Thoracic Oncology, Hôpital Nord, APHM, Marseille/FR
  • 4 Pathology, Mesopath, CRLCC Léon Berard, Lyon/FR
  • 5 Oncology, CRLCC François Baclesse, Caen/FR
  • 6 Pneumologie Et Oncologie Thoracique, HIA Percy, Clamart/FR
  • 7 Pneumologie, CHI Créteil, Créteil/FR
  • 8 Pneumologie, CHU Pontchaillou, Rennes/FR
  • 9 Pneumologie, CH Toulon, Toulon/FR
  • 10 Pneumologie Et Oncologie Thoracique, HCL Lyon-Sud, Pierre-Bénite/FR
  • 11 Pneumologie, CHR du Mans, Le Mans/FR
  • 12 Pneumologie, CHU Charles Nicolle, Rouen/FR
  • 13 Pneumologie, CHU Angers, Angers/FR
  • 14 Oncologie Médicale, Institut Gustave Roussy, Villejuif/FR
  • 15 Oncologie Médicale, Clinique de l'Estuaire, Saint-Nazaire/FR
  • 16 Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris/FR
  • 17 Pulmonology And Thoracic Oncology, CHU de Grenoble, La Tronche/FR
  • 18 Pulmonology And Thoracic Oncology, CHRU de Lille, Lille/FR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2692

Background

No treatment is currently recommended in MPM pts progressing after 1st-line pemetrexed platinum doublet. Disease control rate (DCR) is 

Methods

Multicenter randomized non-comparative phase 2 trial. Eligible pts: age>18, PS 0-1, histologically proved MPM relapsing after 1 or 2 prior lines including pemetrexed/platinum doublet, measurable disease. Randomized pts (1:1) received Nivo 3 mg/kg q2w, or Nivo 3 mg/kg q2w plus Ipi 1 mg/kg q6w, until progression or unacceptable toxicity. Primary endpoint was DCR at 12 weeks.

Results

From April to August 2016, 125 pts were accrued in 20 centers. Males: 80%, median age: 71.8 years (range 32.5-88.1), PS 1: 62.4%, epithelioïd 83.2%, 1 previous line: 69.6%.70%of pts received at least 3 cycles of either treatment. 12 weeks-DCR assessed by BICR in the first 108 pts was 44.4% [CI95%: 31.2-57.7%] with Nivo (n = 54), and 50.0% [36.7-63.3%] with Nivo+Ipi (n = 54). ORR was 18.5% [8.2-28.9%] with Nivo, and 27.8% [15.8-39.7%] with Nivo+Ipi. Grade 3/4 toxicities were slightly increased in the combo arm (Nivo: 12.7%/0% vs. Nivo+Ipi: 22.9%/3.3%) with 3 treatment-related deaths in the combo arm. Median follow-up was15 months (July, 31th 2017), median PFS was 4.0 months, 95%CI[2.8-5.7] and 5.6 months 95%CI[3.2-8.4] in Nivo and Nivo+Ipi arms, respectively. Median OS was 13.6 months, 95%CI[6.7-NR] and not reached in Nivo and Nivo+Ipi arms, respectively. 12-months OS were 51% and 58% in Nivo and Nivo+Ipi arms respectively. PD-L1 IHC (mAb 28.8) available in 99/125 patients, was positive (>1% PDL1+ tumor cells) in 41.4%. Positive PD-L1 IHC did not predict longer PFS or OS, either in the whole population or in each treatment group separately.

Conclusions

Both Nivo or Nivo+Ipi reached their endpoint in 2nd/3rd line MPM pts without any unexpected toxicity, leading to meaningful progression-free and overall survivals. These updated results support the efficacy of checkpoints inhibitors in MPM patients, deserving future phase 3 trials.

Clinical trial identification

NCT02716272

Legal entity responsible for the study

Intergroupe Francophone de Cancérologie Thoracique (IFCT)

Funding

BMS

Disclosure

G. Zalcman: Advisory board for MSD, Boehringer-Ingelheim, BMS Grants and personal fees from BMS, Roche, Astra-Zeneca, Novartis. Compensation for meeting attendance and accommodation: Roche, Astra-Zeneca, BMS, Pfizer. J. Mazieres: Research funding from BMS & Roche. L. Greillier: Honoraria from Boehringer-Ingelheim, BMS, Lilly, Pfizer, Astra-Zeneca, Novartis, Roche. Avisory role for Borhingher-Ingelheim, BMS, Roche. Research funding for my institution from Roche. Travel and accommodation from Lilly, Pfizer, Boehringer-Ingelheim. I. Monnet: Research funding from MSD, Astellas Oncology, Astra-Zeneca. Travel & accommodation from MSD, Novartis. R. Corre: Advisory role for Roche, Lilly, BMS, Astra-Zeneca. Travel & accommodations from Boerhinger-Ingelheim, Amgen, Roche. Honoraria from Boerhinger-Ingelheim. C. Audigier-Valette: Advisory role: Roche, Pfizer, Boerhinger, Novartis, Astra-Zeneca, Lilly, Amgen, BMS, Sysmex, MSD, Clovis Oncology, Medimmune. Travel/accommodations from Roche, Pfizer, Lilly, Amgen, Novartis, BMS, MSD, Medimmune. M. Locatelli-Sanchez: Travel & accommodation from Pierre Fabre and Boerhinger-Ingelheim. O. Molinier: Advisory role for BMS, Boerhinger-Ingelheim, Astra-Zeneca, Novartis, Roche. D. Planchard: Avisory Role for Lilly, BMS, Pfizer, Clovis oncology, MSD, Sanofi, Astra-Zeneca, Novartis, Roche. Research funding from Novartis. D. Moro-Sibilot: Honoraria from La Lettre du Cancérologue, Roche, BMS, Pfizer, Boerhinger, Lilly, Astra-Zeneca. Travel and accommodation from Roche. A. Scherpereel: Invitations at international meetings (ASCO, iMig, CPLF, AACR): Roche, MSD, BMS, France Oxygene. Honoraria for participation to scientific or advisory boards, organized by Astra-Zeneca, BMS, Boehringer-Ingelheim, MSD, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.